Kelly Norsworthy

16PUBLICATIONS
76CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Toxicology (incl. clinical toxicology)Molecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Apr 30, 2026
Real-World Treatment Patterns and Outcomes Among Patients With Newly Diagnosed AML in the United States.

|Jan 09, 2026
Project 5 in 5: Paving the Way for Increasing Pragmatism in Clinical Oncology Trials.

Steven Clark Cunningham, Kelly Norsworthy, Jennifer J Gao

|Oct 24, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

Nina Kim, E Dianne Pulte, Lori A Ehrlich

|Jul 01, 2025
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.

Ashley C Woods, E Dianne Pulte, Xin Wang

|May 28, 2025
FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD.

Kelly J Norsworthy, Donna R Rivera, Joseph Wynne

|Oct 30, 2024
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation.

Ashley C Woods, Kelly J Norsworthy, Moran Choe

Pageof 3

Frequent Collaborators

10 joint publications

R Angelo de Claro

8 joint publications

Marc Theoret

8 joint publications

Jonathon Vallejo

7 joint publications

Richard Pazdur